Pall Corporation signed a new contract worth more than $7 million with Exothera, a CDMO based in Belgium, that will establish a suspension-based manufacturing platform of up to 2000L, using a range of technologies including Allegro™ STR single-use bioreactors. The new installation allows for the production of a variety of viral vectors for gene therapies and viral vector-based vaccines. Source: Genetic Engineering News 2/7/2021